- Home
- FHTX
as 12-20-2024 4:00pm EST
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 513.7M | IPO Year: | 2020 |
| Target Price: | $13.80 | AVG Volume (30 days): | 197.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.70 - $10.25 | Next Earning Date: | 11-04-2024 |
| Revenue: | $25,515,000 | Revenue Growth: | -21.66% |
| Revenue Growth (this year): | -7.21% | Revenue Growth (next year): | 11.54% |
Latest Foghorn Therapeutics Inc. News
FHTX Breaking Stock News: Dive into FHTX Ticker-Specific Updates for Smart Investing
TipRanks
4 days ago
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright
TipRanks
5 days ago
Foghorn Therapeutics Advances Precision Oncology Pipeline
MT Newswires
6 days ago
Wedbush Cuts Price Target on Foghorn Therapeutics to $10 From $13, Keeps Outperform Rating
MT Newswires
6 days ago
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
MT Newswires
6 days ago
Foghorn Therapeutics Discontinues Development of FHD-286 Clinical Program; Shares Fall Pre-Bell
GlobeNewswire
6 days ago
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Zacks
10 days ago
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)
Zacks
23 days ago
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Compare FHTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FHTX Foghorn Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.